Gene drug ‘only hope’ for Turkish child, but costs millions
Zolgensma may stop five-year-old Yusuf Polat's spinal muscular atrophy from progressing, but it costs $2.1m.Zolgensma may stop five-year-old Yusuf Polat's spinal muscular atrophy from progressing, but it costs $2.1m.